| Dr Beth Erin Julian, MD | |
|
625 S Fair Oaks Ave, Suite 260, Pasadena, CA 91105-2613 | |
| (626) 795-5848 | |
| Not Available |
| Full Name | Dr Beth Erin Julian |
|---|---|
| Gender | Female |
| Speciality | Obstetrics & Gynecology |
| Location | 625 S Fair Oaks Ave, Pasadena, California |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1275645236 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | A62155 (California) | Primary |
| Entity Name | Usc Care Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902846306 PECOS PAC ID: 0446157747 Enrollment ID: O20050512000412 |
News Archive
NUT midline carcinoma (NMC) is a cancer without a cure, and one that affects all age groups. NMC is a rapid-growth disease with an average survival time of four and a half months after diagnosis, making the development of clinical trials for potential therapies or cures for this cancer difficult, to say the least.
Memorial Sloan-Kettering Cancer Center (MSKCC) researchers have found that melanoma patients with a family history of melanoma and/or dysplastic nevi (abnormal moles) are at high risk of developing multiple primary melanomas (MPM). Researchers recommend more intensive follow up for these high-risk patients.
Pure Protein, L.L.C., a biopharmaceutical company specializing in diagnostic and therapeutic reagents for use in immunology research and development, has announced that Chief Scientist William Hildebrand, Ph.D., and his team, have developed soluble Class II human leukocyte antigens (HLA). This represents a significant technology breakthrough that can dramatically impact multiple pharmaceutical and medical sectors and has enormous market potential. Autoimmune disease is a key area of interest for HLA research and product development.
TSO3 Inc., an innovator in sterilization technology for medical devices in healthcare settings, today announced that the Company has received purchase orders for multiple devices from the US. The orders are the result of the collaborative relationship between Getinge Infection Control, its sales and service provider, and the Company.
Why are black older adults at higher risk of repeat hospital admission after a heart attack? Treatment at hospitals with higher rates of missed nursing care may be a contributing factor, reports a study in the May issue of Medical Care.
› Verified 1 days ago
| Entity Name | Obhg California Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215258892 PECOS PAC ID: 8729276795 Enrollment ID: O20101217000826 |
News Archive
NUT midline carcinoma (NMC) is a cancer without a cure, and one that affects all age groups. NMC is a rapid-growth disease with an average survival time of four and a half months after diagnosis, making the development of clinical trials for potential therapies or cures for this cancer difficult, to say the least.
Memorial Sloan-Kettering Cancer Center (MSKCC) researchers have found that melanoma patients with a family history of melanoma and/or dysplastic nevi (abnormal moles) are at high risk of developing multiple primary melanomas (MPM). Researchers recommend more intensive follow up for these high-risk patients.
Pure Protein, L.L.C., a biopharmaceutical company specializing in diagnostic and therapeutic reagents for use in immunology research and development, has announced that Chief Scientist William Hildebrand, Ph.D., and his team, have developed soluble Class II human leukocyte antigens (HLA). This represents a significant technology breakthrough that can dramatically impact multiple pharmaceutical and medical sectors and has enormous market potential. Autoimmune disease is a key area of interest for HLA research and product development.
TSO3 Inc., an innovator in sterilization technology for medical devices in healthcare settings, today announced that the Company has received purchase orders for multiple devices from the US. The orders are the result of the collaborative relationship between Getinge Infection Control, its sales and service provider, and the Company.
Why are black older adults at higher risk of repeat hospital admission after a heart attack? Treatment at hospitals with higher rates of missed nursing care may be a contributing factor, reports a study in the May issue of Medical Care.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Beth Erin Julian, MD Po Box 31309, Los Angeles, CA 90031-0309 Ph: (626) 795-5848 | Dr Beth Erin Julian, MD 625 S Fair Oaks Ave, Suite 260, Pasadena, CA 91105-2613 Ph: (626) 795-5848 |
News Archive
NUT midline carcinoma (NMC) is a cancer without a cure, and one that affects all age groups. NMC is a rapid-growth disease with an average survival time of four and a half months after diagnosis, making the development of clinical trials for potential therapies or cures for this cancer difficult, to say the least.
Memorial Sloan-Kettering Cancer Center (MSKCC) researchers have found that melanoma patients with a family history of melanoma and/or dysplastic nevi (abnormal moles) are at high risk of developing multiple primary melanomas (MPM). Researchers recommend more intensive follow up for these high-risk patients.
Pure Protein, L.L.C., a biopharmaceutical company specializing in diagnostic and therapeutic reagents for use in immunology research and development, has announced that Chief Scientist William Hildebrand, Ph.D., and his team, have developed soluble Class II human leukocyte antigens (HLA). This represents a significant technology breakthrough that can dramatically impact multiple pharmaceutical and medical sectors and has enormous market potential. Autoimmune disease is a key area of interest for HLA research and product development.
TSO3 Inc., an innovator in sterilization technology for medical devices in healthcare settings, today announced that the Company has received purchase orders for multiple devices from the US. The orders are the result of the collaborative relationship between Getinge Infection Control, its sales and service provider, and the Company.
Why are black older adults at higher risk of repeat hospital admission after a heart attack? Treatment at hospitals with higher rates of missed nursing care may be a contributing factor, reports a study in the May issue of Medical Care.
› Verified 1 days ago
Dr. Jonathan Nei-kim Tam, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 105 N Hill Ave Ste 203, Pasadena, CA 91106 Phone: 626-449-2800 Fax: 626-795-5145 | |
John Gordon Wilcox, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 333 S Arroyo Pkwy, Pasadena, CA 91105 Phone: 626-440-9161 Fax: 626-585-1603 | |
Paul Sc Lin, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 960 E Green St Ste L-60, Pasadena, CA 91106 Phone: 626-793-3339 Fax: 626-793-3118 | |
Jeffrey Robert Nelson, D.O. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 333 S Arroyo Pkwy, Pasadena, CA 91105 Phone: 626-440-9161 Fax: 626-585-1603 | |
Dr. James Armen Macer, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 10 Congress St, Suite 400, Pasadena, CA 91105 Phone: 626-449-6223 Fax: 626-449-0035 | |
Aaron J Epstein, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 50 Alessandro Pl Ste 210, Pasadena, CA 91105 Phone: 626-514-0060 Fax: 626-514-0062 | |
Dr. George Toshinori Matsuda, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 10 Congress St, Suite 400, Pasadena, CA 91105 Phone: 626-449-6223 Fax: 626-449-0035 |